
The Obesity Revolution
A new generation of obesity drugs is transforming patients’ lives, dividing medical experts, and spurring the biggest business battle in years. Known as incretin mimetics or GLP-1-based drugs, this medication class is seen as the first of a very long line that could have the medical and societal impact of blockbusters like Viagra, Lipitor, and Prozac. Like them, these weight-loss drugs have the potential to reshape the way we think of what it means to be sick and what it takes to be healthy.
Most Read


STAT Plus: ‘Emotional hunger’ vs. ‘hungry gut’: The attempt to subtype obesity and tailor treatments

Watch: The strange history of BMI, the body mass index

STAT Plus: Mix-it-yourself Wegovy? Some are trying risky sources for weight-loss drugs

STAT Plus: The unexpected alliance lobbying for Medicare to pay for new obesity drugs

STAT Plus: Eli Lilly tightens access to diabetes drug, frustrating some people with obesity
